<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63727">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859637</url>
  </required_header>
  <id_info>
    <org_study_id>EP06-401</org_study_id>
    <nct_id>NCT01859637</nct_id>
  </id_info>
  <brief_title>The Study on the Immunogenicity, Safety, and Efficacy of Zarzio® in Patients With Severe Chronic Neutropenia</brief_title>
  <official_title>Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>Germany: BfArM</authority>
    <authority>Sweden: MPA</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to investigate the safety, immunogenicity and the efficacy of Zarzio
      under chromic administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Immunogenicity: Incidences of antibodies will be determinated</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Descreptive analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: to assess the incidence of (S)AEs</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>vital signs, blood chemistry, urinanalysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Severe Chronic Neutropenia</condition>
  <arm_group>
    <arm_group_label>Zarzio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eligible patients will be treated with Zarzio</intervention_name>
    <arm_group_label>Zarzio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with established congenital, cyclic or idiopatc severe chronic neutropenia
             having an indication for treatment with Zarzio

        Exclusion Criteria:

          -  Chemotherapy-induced neutropenia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz Biopharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandoz Biopharmaceuticals</last_name>
    <phone>+49 8024 476 0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MHH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Zeidler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Institut</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tesfa, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
